Supernus Pharmaceuticals
SUPN
43.05
+0.22
+0.51%
Supernus Pharmaceuticals
US · SUPN
#2636 by market cap
Listed 1970
43.05
+0.22
+0.51%
Live - 5344 symbols - heartbeat 250s ago
· 2026-10-08 07:26
Pre-market
42.12
-2.16%
After-hours
43.05
0.00%
- Market cap
- 2.51B
- P/E (TTM)i
- -22.42
- P/Bi
- 2.43
- EPSi
- -0.68
- Div yieldi
- 0.00%
- 52W posi
- 13%
Reader sentiment
Are you bullish or bearish on SUPN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.01, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +8.63% YoY
Margins
- Gross margin
- 89.63%
- Operating margin
- -5.13%
- Net margin
- -5.36%
Key ratios & quality
- Altman Z-Scorei
- 5.01
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 408.90M | 392.76M | 520.40M | 579.78M | 667.24M | 607.52M | 661.82M | 718.95M |
| Gross profit | 393.54M | 376.10M | 467.94M | 504.71M | 580.02M | 523.74M | 583.91M | 644.39M |
| Selling & admin expenses | 154.70M | 153.25M | 200.68M | 304.76M | 377.22M | 336.36M | 321.58M | 485.56M |
| Research & development | 89.21M | 69.10M | 75.96M | 90.47M | 74.55M | 91.59M | 108.80M | 106.24M |
| Operating profit | 144.44M | 148.57M | 175.60M | 79.50M | 45.61M | 13.40M | 75.56M | -36.86M |
| Pretax profit | 140.18M | 147.49M | 168.65M | 73.18M | 60.74M | 2.77M | 97.87M | -49.03M |
| Tax | 29.18M | 34.43M | 41.70M | 19.75M | 32.00K | 1.45M | 24.01M | -10.48M |
| Net profit | 110.99M | 113.06M | 126.95M | 53.42M | 60.71M | 1.32M | 73.87M | -38.55M |
| Basic EPS | 2 | 2 | 2 | 1 | 1 | 0 | 1 | -1 |
| Diluted EPS | 2.05 | 2.10 | 2.36 | 0.98 | 1.04 | 0.02 | 1.32 | -0.68 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 149.82M | 165.45M | 192.10M | 211.57M | 207.71M | 219.06M |
| Gross profit | 134.06M | 148.63M | 173.14M | 188.57M | 184.31M | 185.39M |
| Selling & admin expenses | 89.94M | 93.55M | 179.68M | 122.39M | 125.17M | 133.64M |
| Research & development | 26.93M | 22.12M | 29.37M | 27.83M | 39.44M | 29.46M |
| Operating profit | -2.60M | 12.14M | -60.23M | 13.82M | -5.94M | -3.04M |
| Pretax profit | -5.83M | 16.67M | -57.95M | -1.91M | -5.95M | -57.65M |
| Tax | 6.00M | -5.83M | -12.84M | 2.19M | -3.66M | 723.00K |
| Net profit | -11.83M | 22.50M | -45.12M | -4.11M | -2.29M | -58.37M |
| Basic EPS | 0 | 0 | -1 | 0 | 0 | -1 |
| Diluted EPS | -0.21 | 0.40 | -0.80 | -0.07 | -0.04 | -1.01 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 493.49M | 472.64M | 630.42M | 601.59M | 734.15M | 493.11M | 686.07M | 644.18M |
| Cash & ST investments | 356.02M | 347.07M | 422.53M | 339.68M | 461.33M | 254.87M | 453.61M | 308.67M |
| Inventory | 25.66M | 26.63M | 48.33M | 85.96M | 91.54M | 77.41M | 54.29M | 82.39M |
| Total assets | 977.81M | 1.16B | 1.50B | 1.69B | 1.70B | 1.28B | 1.37B | 1.45B |
| Total current liabilities | 161.35M | 160.59M | 245.11M | 315.38M | 687.96M | 290.20M | 292.40M | 338.17M |
| Short-term debt | -- | 2.83M | 3.76M | 6.48M | 408.76M | 8.33M | 6.89M | 10.61M |
| Long-term debt | 329.46M | 345.17M | 361.75M | 379.25M | -- | -- | -- | -- |
| Total liabilities | 524,788,000.00 | 564,854,000.00 | 759,244,000.00 | 873,301,000.00 | 816,304,000.00 | 356,157,000.00 | 332,340,000.00 | 390,934,000.00 |
| Total equity | 453.02M | 595.43M | 744.86M | 815.85M | 886.20M | 921.52M | 1.04B | 1.06B |
| Retained earnings | 86.49M | 199.55M | 326.50M | 379.92M | 481.25M | 482.56M | 556.43M | 517.88M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 687.58M | 738.87M | 593.89M | 644.18M | 731.58M | 723.50M |
| Cash & ST investments | 463.59M | 522.60M | 281.16M | 308.67M | 384.24M | 372.07M |
| Inventory | 49.42M | 44.02M | 79.40M | 82.39M | 87.06M | 83.92M |
| Total assets | 1.35B | 1.38B | 1.42B | 1.45B | 1.50B | 1.43B |
| Total current liabilities | 281.77M | 286.36M | 330.63M | 338.17M | 373.93M | 347.38M |
| Short-term debt | 5.94M | 7.39M | 10.79M | 10.61M | 10.64M | 10.74M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 316,585,000.00 | 318,505,000.00 | 370,087,000.00 | 390,934,000.00 | 423,920,000.00 | 396,883,000.00 |
| Total equity | 1.03B | 1.06B | 1.05B | 1.06B | 1.08B | 1.03B |
| Retained earnings | 544.60M | 567.10M | 521.98M | 517.88M | 515.58M | 457.21M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 128.99M | 143.13M | 138.40M | 127.13M | 116.83M | 111.09M | 171.95M | 47.33M |
| Depreciation & amortization | 7.06M | 6.66M | 18.14M | 32.60M | 85.54M | 84.86M | 80.41M | 91.56M |
| Free cash flow | 128.14M | 141.74M | 134.71M | 125.08M | 116.41M | 110.53M | 171.23M | 45.99M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 11.58M | 3.93M | 4.36M | 7.10M | 12.42M | 6.61M | 14.91M | 37.62M |
| Ending cash balance | 192.25M | 181.38M | 288.64M | 203.43M | 93.12M | 75.05M | 69.33M | 129.90M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 30.60M | 58.54M | -61.66M | 19.86M | 66.52M | -4.81M |
| Depreciation & amortization | 20.38M | 21.36M | 24.81M | 25.02M | 26.13M | 25.75M |
| Free cash flow | 30.27M | 58.08M | -61.79M | 19.43M | 66.52M | -5.38M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 2.04M | 3.28M | 23.74M | 8.56M | 13.67M | 4.12M |
| Ending cash balance | 115.85M | 144.71M | 152.82M | 129.90M | 186.32M | 181.40M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 30.81 | 21.57 | 18.94 | 6.85 | 7.13 | 0.15 | 7.55 | -3.68 |
| ROA %i | 15.83 | 10.58 | 9.53 | 3.35 | 3.58 | 0.09 | 5.58 | -2.73 |
| ROIC %i | 16.58 | 12.95 | 12.26 | 5.23 | 3.58 | -0.41 | 6.07 | -4.51 |
| 5-year avg ROE %i | 22.64 | 32.84 | 32.30 | 20.62 | 17.06 | 10.93 | 8.12 | 3.60 |
| EBIT margin %i | 38.71 | 43.33 | 36.97 | 16.66 | 10.16 | 0.85 | 14.79 | -6.82 |
| FCF / sales %i | 31.34 | 35.75 | 25.93 | 21.57 | 17.45 | 18.19 | 25.87 | 6.40 |
| Current ratioi | 3.06 | 2.94 | 2.57 | 1.91 | 1.07 | 1.70 | 2.35 | 1.90 |
| Quick ratioi | 2.84 | 2.71 | 2.30 | 1.55 | 0.91 | 1.38 | 2.04 | 1.47 |
| Debt / assetsi | 33.69 | 32.62 | 27.55 | 25.28 | 26.12 | 3.25 | 2.51 | 2.82 |
| LT debt / equityi | 72.73 | 63.08 | 55.12 | 51.55 | 4.06 | 3.60 | 2.64 | 2.86 |
| Interest coveragei | 8.74 | 7.50 | 8.10 | 4.12 | 9.59 | 2.15 | -- | -- |
| Revenue CAGR (3Y) %i | 40.49 | 22.24 | 19.86 | 12.34 | 19.32 | 5.30 | 4.51 | 2.52 |
| Net income CAGR (3Y) %i | 99.67 | 7.42 | 30.38 | -21.63 | -18.72 | -78.20 | 11.40 | -- |
| FCF CAGR (3Y) %i | 58.11 | 29.54 | 6.15 | -0.80 | -6.35 | -6.38 | 11.03 | -26.62 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 6.32 | 6.38 | -1.86 | -3.68 | -2.75 | -10.49 |
| ROA %i | 4.67 | 4.78 | -1.38 | -2.73 | -2.04 | -7.82 |
| ROIC %i | 4.94 | 4.81 | -3.19 | -4.51 | -3.28 | -10.72 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 14.90 | 14.05 | -0.97 | -6.82 | -6.74 | -14.59 |
| FCF / sales %i | 24.45 | 27.94 | 10.38 | 6.40 | 10.59 | 2.26 |
| Current ratioi | 2.44 | 2.58 | 1.80 | 1.90 | 1.96 | 2.08 |
| Quick ratioi | 2.16 | 2.32 | 1.37 | 1.47 | 1.51 | 1.68 |
| Debt / assetsi | 2.40 | 2.30 | 2.97 | 2.82 | 2.73 | 2.81 |
| LT debt / equityi | 2.56 | 2.29 | 2.99 | 2.86 | 2.81 | 2.85 |
| Interest coveragei | -- | -- | -- | -- | -- | -52.33 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 07:26:40 · For reference only, not investment advice and not tailored to your situation.